| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2018: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2016: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
|
|---|
| Outline of Final Research Achievements |
Two types of arteriosclerosis, atherosclerosis and vascular calcification, have distinct pathophysiology. It has been well established that atherosclerosis is caused by cholesterol and that statins that lowers serum cholesterol levels have been widely used as therapeutic reagents for atherosclerosis. In contrast, neither therapeutic targets nor effective reagents have not been identified for vascular calcification. Recent studies have demonstrated that the severity of vascular calcification are correlated with serum levels of calciprotein particles (CPP), colloidal particles containing calcium-phosphate precipitates. In this study, we have identified a compound that potentially alters physical properties of CPP to reduce the ability of CPP to induce cell damage and calcification. Using an animal model for vascular calcification, we have succeeded in showing that administration of the compound is effective in the treatment of vascular calcification.
|
